Case report demonstrates safety and effectiveness of risankizumab in psoriasis management, highlighting its potential for patients with underlying malignancies.
Risankizumab (RZB) is a humanized monoclonal antibody that selectively targets interleukin-23 (IL-23). It has proven particularly effective in treating psoriasis, a common chronic inflammatory skin disease. However, its use remains poorly documented in certain populations, including patients with a history of solid organ transplantation or recent/active malignancy. We present a case of successful and well-tolerated treatment with RZB over an 18-month follow-up period in a patient with multiple comorbidities, including liver transplantation, recurrent hepatocellular carcinoma (HCC) with adrenal metastases, and severe chronic kidney disease.
No takes yet. Share an insight, caveat, or question.
Sylvain et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: